Literature DB >> 19284227

Predictors of hearing preservation after stereotactic radiosurgery for acoustic neuroma.

Hideyuki Kano1, Douglas Kondziolka, Aftab Khan, John C Flickinger, L Dade Lunsford.   

Abstract

OBJECT: Many patients with acoustic neuromas (ANs) have hearing function at diagnosis and desire to maintain it. To date, radiosurgical techniques have been focused on conformal irradiation of the tumor mass, with less attention to inner ear structures for which there was scant radiobiological information. The authors of this study evaluated tumor control and hearing preservation as they relate to tumor volume, imaging characteristics, and nerve and cochlear radiation dose following stereotactic radiosurgery (SRS) using the Gamma Knife.
METHODS: Seventy-seven patients with ANs had serviceable hearing (Gardner-Robertson [GR] Class I or II) and underwent SRS between 2004 and 2007. This interval reflected more recent measurements of inner ear dosimetry during the authors' 21-year experience. The median patient age was 52 years (range 22-82 years). No patient had undergone any prior treatment for the ANs. The median tumor volume was 0.75 cm(3) (range 0.07-7.7 cm(3)), and the median radiation dose to the tumor margin was 12.5 Gy (range 12-13 Gy). At diagnosis, a greater distance from the lateral tumor to the end of the internal auditory canal correlated with better hearing function.
RESULTS: At a median of 20 months after SRS, no patient required any other additional treatment. Serviceable hearing was preserved in 71% of all patients and in 89% (46 patients) of those with GR Class I hearing. Significant prognostic factors for maintaining the same GR class included (all pre-SRS) GR Class I hearing, a speech discrimination score (SDS) >or= 80%, a pure tone average (PTA) < 20 dB, and a patient age < 60 years. Significant prognostic factors for serviceable hearing preservation were (all pre-SRS) GR Class I hearing, an SDS >or= 80%, a PTA < 20 dB, a patient age < 60 years, an intracanalicular tumor location, and a tumor volume < 0.75 cm(3). Patients who received a radiation dose of < 4.2 Gy to the central cochlea had significantly better hearing preservation of the same GR class. Twelve of 12 patients < 60 years of age who had received a cochlear dose < 4.2 Gy retained serviceable hearing at 2 years post-SRS.
CONCLUSIONS: As currently practiced, SRS with the Gamma Knife preserves serviceable hearing in the majority of patients. Tumor volume and anatomy relate to the hearing level before radiosurgery and influence technique. A low radiosurgical dose to the cochlea enhances hearing preservation.

Entities:  

Mesh:

Year:  2009        PMID: 19284227     DOI: 10.3171/2008.12.JNS08611

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  29 in total

1.  Hearing Preservation in Stereotactic Radiosurgery for Vestibular Schwannoma.

Authors:  Anthony M Tolisano; Jacob B Hunter
Journal:  J Neurol Surg B Skull Base       Date:  2019-01-10

2.  The Changing Paradigm for the Surgical Treatment of Large Vestibular Schwannomas.

Authors:  Roy Thomas Daniel; Constantin Tuleasca; Alda Rocca; Mercy George; Etienne Pralong; Luis Schiappacasse; Michele Zeverino; Raphael Maire; Mahmoud Messerer; Marc Levivier
Journal:  J Neurol Surg B Skull Base       Date:  2018-08-23

3.  Increased cochlear radiation dose predicts delayed hearing loss following both stereotactic radiosurgery and fractionated stereotactic radiotherapy for vestibular schwannoma.

Authors:  Kunal S Patel; Edwin Ng; Taranjit Kaur; Tyler Miao; Tania Kaprealian; Percy Lee; Nader Pouratian; Michael T Selch; Antonio A F De Salles; Quinton Gopen; Stephen Tenn; Isaac Yang
Journal:  J Neurooncol       Date:  2019-09-24       Impact factor: 4.130

Review 4.  The biology of radiosurgery and its clinical applications for brain tumors.

Authors:  Douglas Kondziolka; Samuel M Shin; Andrew Brunswick; Irene Kim; Joshua S Silverman
Journal:  Neuro Oncol       Date:  2014-09-28       Impact factor: 12.300

5.  Stereotactic radiotherapy of vestibular schwannoma : Hearing preservation, vestibular function, and local control following primary and salvage radiotherapy.

Authors:  Florian Putz; Jan Müller; Caterina Wimmer; Nicole Goerig; Stefan Knippen; Heinrich Iro; Philipp Grundtner; Ilker Eyüpoglu; Karl Rössler; Sabine Semrau; Rainer Fietkau; Sebastian Lettmaier
Journal:  Strahlenther Onkol       Date:  2016-12-07       Impact factor: 3.621

6.  Five-year outcomes following hypofractionated stereotactic radiotherapy delivered in five fractions for acoustic neuromas: the mean cochlear dose may impact hearing preservation.

Authors:  Zhiping Chen; Keiichi Takehana; Takashi Mizowaki; Megumi Uto; Kengo Ogura; Katsuyuki Sakanaka; Yoshiki Arakawa; Yohei Mineharu; Yuki Miyabe; Nobutaka Mukumoto; Susumu Miyamoto; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2018-03-19       Impact factor: 3.402

7.  Stereotactic radiosurgery for the treatment and palliation of base of skull metastases.

Authors:  David A Clump; Jonathan E Leeman; Rodney E Wegner; Steven A Burton; Arlan H Mintz; Dwight E Heron
Journal:  J Radiosurg SBRT       Date:  2013

8.  Long term results of primary radiosurgery for vestibular schwannomas.

Authors:  Stephen Johnson; Hideyuki Kano; Andrew Faramand; Matthew Pease; Aya Nakamura; Mohab Hassib; David Spencer; Nathaniel Sisterson; Amir H Faraji; Yoshio Arai; Edward Monaco; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  J Neurooncol       Date:  2019-09-18       Impact factor: 4.130

Review 9.  The emerging role of hearing loss rehabilitation in patients with vestibular schwannoma treated with Gamma Knife radiosurgery: literature review.

Authors:  Carlotta Morselli; N Boari; M Artico; M Bailo; L O Piccioni; I Giallini; M de Vincentiis; P Mortini; P Mancini
Journal:  Neurosurg Rev       Date:  2020-02-06       Impact factor: 3.042

10.  Long-term hearing outcomes after gamma knife surgery in patients with vestibular schwannoma with hearing preservation: evaluation in 92 patients with serial audiograms.

Authors:  Toshinori Hasegawa; Takenori Kato; Takashi Yamamoto; Takehiro Naito; Naoki Kato; Jun Torii; Kazuki Ishii
Journal:  J Neurooncol       Date:  2018-04-17       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.